Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From XenoPort, Inc.
The Ireland-headquartered firm will advance the candidate into US and EU narcolepsy studies as part of its pipeline diversification project as portfolio products are set to lose their patent exclusivity.
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.
This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.
- Controlled Release
- Drug Delivery
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.